Schedule Of Information For The Company's Operating Segments |
Information for the Company's reportable segments for the three months ended June 30, 2019 and 2018 are as follows: | | | | | | | | | | | | Three Months Ended June 30, 2019 | Consumer Operations | Drug Development | Corporate | Consolidated | Total revenue | $ | 164,705 |
| — |
| — |
| $ | 164,705 |
| Interest income, net | $ | — |
| — |
| 13,361 |
| $ | 13,361 |
| Income (loss) from operations | $ | 11,821 |
| (29,294 | ) | (1,380,665 | ) | $ | (1,398,138 | ) |
| | | | | | | | | | | | Three Months Ended June 30, 2018 | Consumer Operations | Drug Development | Corporate | Consolidated | Total revenue | $ | 245,502 |
| — |
| — |
| $ | 245,502 |
| Interest income, net | $ | — |
| — |
| 51,809 |
| $ | 51,809 |
| Loss from operations | $ | (645,687 | ) | (6,170,488 | ) | (2,287,506 | ) | $ | (9,103,681 | ) |
Information for the Company's reportable segments for the six months ended June 30, 2019 and 2018 are as follows: | | | | | | | | | | | | Six Months Ended June 30, 2019 | Consumer Operations | Drug Development | Corporate | Consolidated | Total revenue | $ | 269,682 |
| — |
| — |
| $ | 269,682 |
| Interest income, net | $ | — |
| — |
| 26,574 |
| $ | 26,574 |
| Loss from operations | $ | (41,287 | ) | (29,678 | ) | (3,570,816 | ) | $ | (3,641,781 | ) |
| | | | | | | | | | | | Six Months Ended June 30, 2018 | Consumer Operations | Drug Development | Corporate | Consolidated | Total revenue | $ | 424,084 |
| — |
| — |
| $ | 424,084 |
| Interest income, net | $ | — |
| — |
| 111,402 |
| $ | 111,402 |
| Loss from operations | $ | (1,902,993 | ) | (10,834,565 | ) | (4,648,943 | ) | $ | (17,386,501 | ) |
|